Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Prothena ( (PRTA) ) has issued an update.
On May 13, 2025, Prothena Corporation plc held its annual general meeting where shareholders approved an amendment to the 2018 Long Term Incentive Plan, increasing the number of shares authorized for issuance by 2,000,000. Additionally, shareholders re-elected board members, ratified the appointment of KPMG LLP as the independent auditor for 2025, and approved executive compensation.
The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
Spark’s Take on PRTA Stock
According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.
Prothena’s overall stock score reflects the company’s challenges with profitability and cash flow despite revenue growth and strong partnerships. The technical analysis indicates a bearish trend, while the valuation shows the typical high-risk, high-reward scenario of a biotech firm heavily reliant on clinical success. The earnings call highlighted strategic strengths but also underscored the critical need for clinical achievements to drive future growth.
To see Spark’s full report on PRTA stock, click here.
More about Prothena
Prothena Corporation plc operates in the biotechnology industry, focusing on the development of therapies for diseases caused by protein misfolding.
Average Trading Volume: 869,109
Technical Sentiment Signal: Sell
Current Market Cap: $370.6M
See more insights into PRTA stock on TipRanks’ Stock Analysis page.